Hydroxyurea in Young Children With Sickle Cell Anemia
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to asses prospectively the safety and efficacy of hydroxyurea
therapy in children with Sickle cell Anemia between ages 18 months and 5 years, with special
emphasis on the ability of hydroxyurea to prevent or reverse chronic organ damage.